immune chekpoint inhibitors for COVID-19: living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

Study type:

	metastatic/adv melanoma (mML)

	mML - L2 - all population
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone	MDX010 Ipi vs gp100
Ipilimumab (10 mg/kg)	CA184-004 Ascierto ...
ipilimumab plus gp100	MDX010 Ipi plus gp100 vs Ipi ... MDX010 Ipi plus gp100 vs gp100
ipilimumab plus SoC	CA184-024
anti-PD-(L)1
nivolumab based treatment
nivolumab alone	CheckMate 037
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)	KEYNOTE-006 ... KEYNOTE-002 ...
pembrolizumab (10mg/kg) 2 weeks	KEYNOTE-006 ...
pembrolizumab (2mg/kg)	KEYNOTE-002 ...